Cell Signaling Technology to Conduct Pilot Study for AstraZeneca to Find Biomarkers of Target Inhibition

Jun 08, 2004

NEW YORK, June 8 (GenomeWeb News) - Cell Signaling Technology will perform a pilot study for AstraZeneca to find biomarkers of target inhibition using its phospho-proteomics technology, the company said yesterday.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Draft Brexit on the Table

Though many details have yet to be worked out, the draft deal for the UK's withdrawal from the EU is giving researchers some hints for what they can expect, Nature News says.

'Really Just a Titi Monkey'

DNA testing has solved a 100-year-old mystery contained in the skull and teeth samples of a now-extinct monkey that once inhabited Jamaica, Gizmodo reports.

Hold the GMO Mosquitoes

As the UN ponders a ban on gene drives, one malaria researcher says there are less dramatic ways to fight the disease in Africa than unleashing GM mosquitoes on a whole continent.

This Week in Nature

In Nature this week: an improved reference genome of the Aedes aegypti mosquito, genomes of four species of truffles, and more.

Main menu